Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

Based on Plasma Exosomes Combined With Multi-omics Analysis to Reveal the Trajectory of Targeted Therapy Resistance and Novel Target Intervention Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations. The main objective is to identify potential biomarkers that can predict the efficacy of targeted therapy through plasma exosomes and to explore strategies to reverse drug resistance to targeted therapy. Biological specimens and medical imaging data will be collected from patients already receiving targeted therapy as a first-line treatment, and followed-up will be conducted to analyze prognosis based on different patterns.

The medical imaging data will be collected retrospectively and prospectively, and the blood samples and tumor tissues will be collected prospectively.

Inclusion Criteria:

• Pathological examination confirmed lung adenocarcinoma
• No other type of tumor was present
• Common sensitive EGFR (Ex19Del L858R or combined with other sites) mutations have been identified
• Receive targeted therapy with or without chemotherapy as first-line treatment
• ≥ 18 years and ≤80 years old

Exclusion Criteria:

• History of other malignant tumors
• Irregular treatment or poor compliance
• Incomplete clinical information or lost to follow-up